Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J CONNOR

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1114924578
CMS profile
765375
Location
KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$701.70

43 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $701.70 43

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J CONNOR

NPI 1114924578 · CMS profile ID 765375

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1114924578?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J CONNOR, NPI 1114924578, CMS profile ID 765375. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114924578?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MICHAEL J CONNOR, NPI 1114924578, CMS profile ID 765375. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114924578?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MICHAEL J CONNOR, NPI 1114924578, CMS profile ID 765375, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1114924578?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

43 matching records · $701.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 43 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–43 of 43.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $14.1612/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897723 CMS
Braintree Laboratories, Inc. $16.1811/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805242053 CMS
Janssen Biotech, Inc. $19.5711/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787851011 CMS
Celgene Corporation $15.2010/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783689961 CMS
Janssen Biotech, Inc. $17.5510/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787851021 CMS
Medtronic, Inc. $12.3510/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827410223 CMS
Celgene Corporation $15.2809/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783689951 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.4309/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897721 CMS
Braintree Laboratories, Inc. $11.3109/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805242049 CMS
Amgen Inc. $13.1909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825617593 CMS
AbbVie Inc. $22.4709/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281807 CMS
AbbVie Inc. $15.4909/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281805 CMS
AbbVie Inc. $16.9509/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281803 CMS
Janssen Biotech, Inc. $14.4008/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787851037 CMS
AbbVie Inc. $15.6408/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281801 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.3008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897717 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.8508/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897715 CMS
Janssen Biotech, Inc. $16.8608/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787851027 CMS
AbbVie Inc. $15.6507/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281799 CMS
AbbVie Inc. $13.2307/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281797 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.8207/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897711 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.9307/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897709 CMS
AbbVie Inc. $13.6007/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281795 CMS
Amgen Inc. $26.3606/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825617589 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.2506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849940239 CMS
AbbVie Inc. $24.1806/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281793 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.2205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850395941 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.9805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897705 CMS
AbbVie Inc. $17.6105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281791 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.9005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850314193 CMS
AbbVie Inc. $23.8204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281789 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.0904/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897703 CMS
BOSTON SCIENTIFIC CORPORATION $15.7204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777712217 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.3304/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819897699 CMS
AbbVie Inc. $4.2404/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281787 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.0203/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850186563 CMS
Merck Sharp & Dohme Corporation $12.6203/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848323485 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.4103/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850197953 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.2703/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850384057 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.6502/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850159817 CMS
AbbVie Inc. $13.2802/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281785 CMS
AbbVie Inc. $12.2901/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794281783 CMS
Braintree Laboratories, Inc. $15.0501/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805242045 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $263.03 7
PY2020 $154.73 7
PY2021 $701.70 43
PY2022 $936.43 54
PY2023 $1,031.69 51
PY2024 $941.95 44
PY2025 $1,025.16 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $17,016.00 4
PY2022 Principal investigator $8,615.60 11
PY2021 Principal investigator $3,311.50 3
PY2020 Principal investigator $131,148.40 321
PY2019 Principal investigator $1,448.10 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

321 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,477.00 12/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 737093439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $155.00 07/20/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737085409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $124.00 07/20/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737085411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $840.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081481
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081497
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081501
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081503
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081505
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081507
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081509
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081519
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081527
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081529
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081531
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081535
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081537
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $730.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081543
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081545
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081549
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081555
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081557
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081561
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $123.50 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $445.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081595
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $356.00 05/18/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737081597
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $411.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $411.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $171.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080881
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080891
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080899
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080901
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080923
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.40 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $126.00 05/13/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737080933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075679
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $880.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075681
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $922.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075683
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075685
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075689
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075693
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075695
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075697
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075699
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075703
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075705
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075707
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075709
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075711
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075719
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075721
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075723
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075725
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075727
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075729
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075731
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075733
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075737
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075739
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075741
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075745
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075751
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075753
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075769
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075779
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075789
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075793
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075795
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075799
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075801
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075805
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075811
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075817
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075819
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075821
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $798.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075881
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075891
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075901
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $922.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075923
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075941
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075951
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075957
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075959
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075961
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $770.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075963
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075969
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075973
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075975
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $279.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $279.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075979
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $279.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $362.50 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $688.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $688.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075989
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $688.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $688.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075993
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $903.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $688.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $678.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737075999
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076001
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076003
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076005
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076007
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076013
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076015
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076017
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $903.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076019
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076023
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076025
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076027
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076029
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076035
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076039
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076041
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $903.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076043
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076047
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076049
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076051
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076055
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076057
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076059
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076065
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $880.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076067
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076069
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076071
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076077
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076079
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076081
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076083
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076087
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076089
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $880.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076091
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076093
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076095
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076099
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076101
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076105
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076107
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076109
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076111
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076113
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $880.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076115
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076117
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076121
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076123
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076125
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076127
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076129
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076131
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $403.00 04/01/2020 Non-covered Recipient Entity
EHRHARDT CLINICAL RESEARCH LLC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 737076135